The pivotal Phase 3 trial for Cylembio® in advanced melanoma showed clinical improvement in progression free survival, but missed its primary endpoint for statistical significance (p=0.056; threshold ...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

The trial tests BNT113, a biological treatment administered via IV injection, in combination with pembrolizumab, an IV infusion, to enhance therapeutic outcomes for patients with specific head and ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Eli Lilly and Company, in collaboration ...

Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Operator: Greetings. Welcome to PDS Biotech Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

No revenue reported as development-stage programs advanced in key clinical trials. These 10 stocks could mint the next wave of millionaires › PDS Biotechnology (NASDAQ:PDSB), a clinical-stage ...